Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872067 | 0.92 | ALDH1A1 (0.43) | ALDH1A1KMT2ATSHRSMN1; SMN2GAA | |
| SCHEMBL13603870 | 0.85 | SMN1; SMN2 (0.48) | ALDH1A1KMT2ATSHRSMN1; SMN2TP53 | |
| SCHEMBL13611429 | 0.84 | SMN1; SMN2 (0.34) | ALDH1A1KMT2ATSHRSMN1; SMN2GSTO1 | |
| SCHEMBL13603869 | 0.84 | TDP1 (0.39) | ALDH1A1KMT2ASMN1; SMN2NR1I2 | |
| SCHEMBL1873292 | 0.83 | TDP1 (0.39) | ALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1866771 | 0.79 | GAA (0.57) | ALDH1A1KMT2ASMN1; SMN2GAATP53 | |
| SCHEMBL14549323 | 0.78 | CRHR1 (0.35) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1875415 | 0.75 | GAA (0.57) | ALDH1A1KMT2ASMN1; SMN2GAATP53 | |
| SCHEMBL3841166 | 0.74 | TDP1 (0.44) | ALDH1A1KMT2ATSHRSMN1; SMN2NR1I2 | |
| SCHEMBL13603867 | 0.74 | BCHE (0.39) | ALDH1A1KMT2ATSHRHSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130048564-A1 | DRAW SOLUTES, METHODS OF FORMING DRAW SOLUTES, AND METHODS OF USING DRAW SOLUTES TO TREAT AN AQUEOUS LIQUID | BATTELLE ENERGY ALLIANCE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048564-A1 | DRAW SOLUTES, METHODS OF FORMING DRAW SOLUTES, AND METHODS OF USING DRAW SOLUTES TO TREAT AN AQUEOUS LIQUID | SLC1A5, AQP4, AQP1 | ALDH1A1 4441/4885KMT2A 4261/4885TSHR 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.